GNOM Global X Fds Genomics & Biotechnology Etf
- 10.305
- +0.015+0.15%
BioNTech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 10.8% HC Wainwright & Co. $113 → $113 Reiterates Buy → Buy 06/03/2024 10.8% HC Wainwright & Co.
If You Invested $100 In This Stock 5 Years Ago, You Would Have $800 Today
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 40.36% on an annualized basis producing an average annual return of 53.19%. Currently, Moderna has a market capitalization of
Breaking Down Natera: 10 Analysts Share Their Views
Natera (NASDAQ:NTRA) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table encapsulates their recent ratings,
Jefferies Initiates Coverage On Natera With Buy Rating, Announces Price Target of $142
Jefferies analyst Tycho Peterson initiates coverage on Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $142.
Natera Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 32.6% Jefferies → $142 Initiates Coverage On → Buy 05/14/2024 12.06% Piper Sandler $110 → $120
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial c
RBC Capital Maintains Outperform on Moderna, Raises Price Target to $160
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and raises the price target from $135 to $160.
Arrowhead Says Phase 3 Trial of Rare Metabolic Disease Asset Plozasiran Meets Goals
Why Intellia Therapeutics Shares Are Trading Higher Monday
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is moving higher Monday after the company announced long-term data from its Phase 1 Study of NTLA-2002.The Details: Intellia's NTLA-2002 is an experimen
WATCH: Dr. Fauci Testifies Live On COVID-19 Pandemic Before House Subcommittee
WATCH: Dr. Fauci Testifies Live On COVID-19 Pandemic Before House Subcommittee
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Intellia Rallies on Phase 1 Data for CRISPR-based HAE Therapy
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study.The study is eval
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
Arrowhead Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 154.24% Chardan Capital $60 → $60 Maintains Buy 05/13/2024 14.41% Morgan Stanley $36 → $27 Main
Market-Moving News for June 3rd
GME: 103% | 'Roaring Kitty' Reveals Massive GME Position On Reddit, Including $65M Call Options: Is He Bringing 'Courage' Back To Wall Street?BPTH: 81% | Bio-Path Presented Interim Results From Phase
Moderna And Merck Announced The First Presentation Of Results From A Planned Analysis From The Phase 2B KEYNOTE-942/mRNA-4157-P201 Study Of MRNA-4157 (V940) Plus Keytruda In Patients With Resected High-risk Melanoma Following Complete Resection (N=157)
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable i
Breaking Down Moderna: 7 Analysts Share Their Views
During the last three months, 7 analysts shared their evaluations of Moderna (NASDAQ:MRNA), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, shed
Intellia Therapeutics Shares Are Trading Higher After the Company Announced Long-term Data From the Phase 1 Portion of the Ongoing Phase 1/2 Study of NTLA-2002.
Intellia Therapeutics Shares Are Trading Higher After the Company Announced Long-term Data From the Phase 1 Portion of the Ongoing Phase 1/2 Study of NTLA-2002.
BioNTech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 12.33% HC Wainwright & Co. $113 → $113 Reiterates Buy → Buy 05/30/2024 12.33% HC Wainwright & C